---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-078207"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:04:43.507668+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics gets UK MHRA approval for LYTENAVA (bevacizumab gamma) for wet AMD

## Summary
- UK MHRA granted Marketing Authorization for LYTENAVA (bevacizumab gamma) to treat wet age-related macular degeneration.
- LYTENAVA is the first and only authorized ophthalmic bevacizumab formulation for wet AMD in the EU and UK.
- Approval leveraged EMA positive opinion under the new International Recognition Procedure.
- This regulatory milestone supports Outlook's commercial strategy in the UK market.

## SEC filing metadata
- accession: 0001104659-24-078207
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/0001104659-24-078207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/tm2418995d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-078207
- JSON: https://secwatch.observer/filing/0001104659-24-078207.json
- Plain text: https://secwatch.observer/filing/0001104659-24-078207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.